SPARC Submits IND Application for SBO-154, a Novel Cancer Therapy

On March 31, 2025, Sun Pharma Advanced Research Company Ltd. (SPARC) submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA). This application supports the further development of SBO-154, a potential treatment for advanced solid tumours. The drug has successfully completed preclinical studies, showing positive results. A global Phase 1 trial has been planned to evaluate its effectiveness in treating solid tumours.

Advancing Cancer Treatment

SBO-154 is the first antibody-drug conjugate (ADC) developed by SPARC. With the IND submission, the drug is set to move forward in clinical trials. Anil Raghavan, CEO of SPARC, stated, “SBO-154’s progress into Phase 1 trials is a major milestone for us, as we aim to enhance cancer treatment worldwide.”

About SBO-154

SBO-154 is a unique ADC that targets the SEA domain of the MUC1 protein, which is found in many solid tumours. The drug binds to this domain with high precision and releases a cancer-fighting agent inside the tumour cells. This disrupts cell division, leading to tumour shrinkage. Biomodifying, a startup at the University of Tel Aviv, licensed the anti-MUC1 antibody used in SBO-154.

About SPARC

SPARC is a clinical-stage biopharmaceutical company focusing on developing innovative treatments to improve patient care. Through research and new drug delivery methods, SPARC aims to provide better treatment options for people worldwide.

As of April 1, 2025, at 9:29 AM IST, Sun Pharma Advanced Research Co share price (NSE: SPARC) is trading at ₹149.92, up ₹2.01 (1.36%) for the day. The stock opened at ₹146.40 and reached a high of ₹150.28 while the day’s low remains ₹146.40. The company has a market capitalisation of ₹4,870 crore. SPARC does not have a P/E ratio or dividend yield listed. Over the past 52 weeks, the stock has hit a high of ₹472.80 and a low of ₹109.30.

Conclusion

With the IND submission for SBO-154, SPARC takes a significant step toward advancing cancer treatment. The upcoming Phase 1 trial will determine its potential to improve patient outcomes.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.